Kida, Daihei
Takahashi, Nobunori
Kaneko, Atsushi
Hirano, Yuji
Fujibayashi, Takayoshi
Kanayama, Yasuhide
Hanabayashi, Masahiro
Yabe, Yuichiro
Takagi, Hideki
Oguchi, Takeshi
Kato, Takefumi
Funahashi, Koji
Matsumoto, Takuya
Ando, Masahiko
Kuwatsuka, Yachiyo
Tanaka, Eiichi
Yasuoka, Hidekata
Kaneko, Yuko
Hirata, Shintaro
Murakami, Kosaku
Sobue, Yasumori
Nishiume, Tsuyoshi
Suzuki, Mochihito
Yokota, Yutaka
Terabe, Kenya
Asai, Shuji
Ishiguro, Naoki
Kojima, Toshihisa
Funding for this research was provided by:
Bristol-Myers Squibb and Ono Pharmaceutical CO., LTD.
Article History
Received: 30 July 2020
Accepted: 2 November 2020
First Online: 12 November 2020
Competing interests
: N.I. received grants, lecture fees, and fees for serving on speakers’ bureaus from Daiichi Sankyo, Takeda Pharmaceutical, Hisamitsu Pharmaceutical, Otsuka Pharmaceutical, Taisho Toyama Pharmaceutical, Kaken Pharmaceutical, Eisai, Janssen Pharmaceutical, Bristol-Myers Squibb, Abbvie Japan, Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Astellas Pharma, and Pfizer Japan. T.K. received lecture fees (< US$5000) from Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, AbbVie, Bristol-Myers Squibb, and Pfizer, and $10000 from Chugai Pharma. N.T. received speaker’s fees from Abbvie Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb (< $5000). Y.H. received speaker’s fees from Abbvie Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb (< $5000). A.K. received lecture fees (< $5000) from Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, Chugai Pharma, Abbvie Japan, Bristol-Myers Squibb, UCB, Janssen, and Pfizer. All other authors have no conflicts of interest to report.